In this exclusive with Sue Dillon, Ph.D., head of Janssen Immunology, she talks candidly about topics such as how the company marries the precommercial and commercial functions.
Chief Editor Rob Wright talks with a few pharma industry icons about what to expect when seeking a board appointment.
The Republican sweep in the 2016 elections hands the enormous power of the Center for Medicare and Medicaid Innovation (CMMI) to the Trump administration. What to do with this power?
The FDA and EMA are giving unprecedented support to addressing the rare disease need, aiming efforts largely at the biotech and specialty pharma companies that are at the forefront of orphan drug development.
The fascinating stories of how Akari Therapeutics and Oncolytics Biotech each faced devastating challenges in their evolution and ultimately reinvented themselves.
The need for discussions regarding guidelines for the development of therapeutics made from human cells, tissues, and cell- and tissue-based products has been building for a long time.
Early last year I had a call with the Global Head of Business Development and APAC (Asia Pacific) Regional Head of Human Resources at a major biotech group. Once initial pleasantries were exchanged the first words from this executive were “Rob, we’re looking to hire a scout ASAP to lead business development in Asia.”
In the precommercial phase, companies invest significant time and money to recruit patients and collect real-world data as well as uncover gaps in current therapies and emerging or anticipated public health needs. That’s why pharmaceutical companies are proactively evaluating and deploying mobile apps to accomplish these goals more quickly, efficiently, and effectively. You can ping someone and get their attention immediately – faster than eliciting a response from an email. This type of engagement is also more conducive to a variety of lifestyles than any other medium.
Proposed changes to the tax code could have a pervasive impact on Pharma’s business strategy.
Beginning in early 2017, life sciences organizations that intend to manufacture and/or market medicinal products within the European Union will be required to comply with the Identification of Medicinal Products (IDMP) regulations, a global framework for identifying medicinal products, set forth by the European Medicines Agency (EMA).
An ideology-driven rush to undo decades of healthcare policy — and the uncertainty this will create — presents real hazards for every segment of the U.S. healthcare system, including the pharmaceutical industry.
In 2002 Liz Lewis joined Takeda where she is currently chief counsel and head of patient advocacy at Takeda Oncology. Lewis sat down with me to share how she helped enhance Takeda Oncology’s patient advocacy organization.
The executive-level participation for Life Science Leader magazine's signature 2017 Outlook issue had an overwhelming. This year’s feature article involved 13 executive life science leaders! In part four of this series, which is a supplement to the feature magazine article, we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?”
The December 2016 issue of Life Science Leader magazine raised the bar in our 2017 Outlook feature article with participation from 13 trendsetters, including pharma leaders, payors, and a representative from the NIH. We hope you enjoy reading their thoughts in this supplement to the magazine’s December 2016 cover feature.
For the second year in a row my travel plans to the biopharmaceutical industry’s yearly kickoff event — the 35th Annual J. P. Morgan Healthcare Conference in San Francisco —was disrupted by weather. And though I once again arrived a day late, there was still plenty to keep me busy during JPM. For example, I still had the opportunity to sit in breakout Q&A sessions involving Alkermes, BMS, Chimerix, GSK, Mylan NV, and Shire. I witnessed company presentations that included AbbVie, CSL Limited, and IDEXX (just to name a few). I attended keynotes involving the Vice President of the United States, Joe Biden, who provided an update on the Cancer Moonshot initiative. I heard political consultants Karl Rove and James Carville debate the pros and cons of repealing and replacing the Affordable Care Act. I even had the opportunity to hear Juan Enriquez, co-author of Evolving Ourselves, share his insights on the next species of human. And while this may seem like a lot, it really only scratches the surface as to the amount of activity that takes place during JPM in January.
Because I live only a day-trip away from San Francisco, it is convenient for me to travel there for industry events — a trek always accompanied by reflective reveries for the hometown of my film-student days. So, for the third time since June, and with another week scheduled for early January, I am once again city-bound, leaving home mid-day and getting into my hotel in plenty of time to make the 5:30 PM reception for the annual Pantheon Awards dinner, held by the California Life Science Association (CLSA).